Business Activities

Takeda remains committed to growing globally as a R&D-driven company.

• All bases
• Research & Development bases
• Production bases
• Marketing bases

Ethical Drug Business

Ethical drugs are Takeda's core business, constituting over 80% of total net sales. Our 5 research centers in the world conduct basic and applied research to create new breakthrough drugs. Development operations in Japan, the U.S. and Europe then work to move these drugs swiftly through development so that better treatments can be delivered as early as possible to patients around the world.

Takeda has an international marketing network including Japan and 13 overseas bases in the U.S., Europe and Asia. From these bases, Takeda markets its original products such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot^®, Enantone^®, Prostap^® and Leuplin^®), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid^®, Ogast^®, Takepron^® and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress^®, Kenzen^® and Amias^®) and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos^®). Including sales through licensees, Takeda's pharmaceuticals are available in around 90 countries worldwide.

A bulk manufacturing plant is currently under construction in Ireland. With the opening of the new plant, bulk production will be underway at two locations: the Hikari plant in Japan, and in Ireland. Takeda manufactures pharmaceuticals in Japan, Europe - through Takeda Ireland Ltd. and Takeda Italia Farmaceutici S.p.A. - and Asia - through Tianjin Takeda Pharmaceuticals Co., Ltd., and P.T. Takeda Indonesia. Takeda Ireland Ltd., which began production in 1999, has been working to meet the sharp increase in demand in the United States and Europe.

Consumer Healthcare Business

In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drug market, in which we now hold the number-two domestic share. The increasing emphasis on self-medication among Japanese consumers should help drive further growth in this field. By taking the viewpoint of consumers, we provide products and services that are closely matched to consumer needs.

Our main brands in the Consumer Healthcare segment are well recognized among Japanese consumers and include Alinamin^® (vitamin B1 derivative preparations, etc.), Benza^® (cold remedies).

Restructuring of Businesses

In order to concentrate management resources into pharmaceutical businesses, Takeda has been restructuring our non-pharmaceutical businesses as originally planned in the 2001-2005 Medium-Term Management Plan.